HRP20210862T1 - Liječenje infekcije hepatitis delta virusom pomoću interferona lambda - Google Patents
Liječenje infekcije hepatitis delta virusom pomoću interferona lambda Download PDFInfo
- Publication number
- HRP20210862T1 HRP20210862T1 HRP20210862TT HRP20210862T HRP20210862T1 HR P20210862 T1 HRP20210862 T1 HR P20210862T1 HR P20210862T T HRP20210862T T HR P20210862TT HR P20210862 T HRP20210862 T HR P20210862T HR P20210862 T1 HRP20210862 T1 HR P20210862T1
- Authority
- HR
- Croatia
- Prior art keywords
- interferon lambda
- treatment
- use according
- patient
- serum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297759P | 2016-02-19 | 2016-02-19 | |
| EP17753966.5A EP3416675B9 (en) | 2016-02-19 | 2017-02-17 | Treatment of hepatitis delta virus infection with interferon lambda |
| PCT/US2017/018466 WO2017143253A1 (en) | 2016-02-19 | 2017-02-17 | Treatment of hepatitis delta virus infection with interferon lambda |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210862T1 true HRP20210862T1 (hr) | 2021-09-17 |
Family
ID=59625481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210862TT HRP20210862T1 (hr) | 2016-02-19 | 2017-02-17 | Liječenje infekcije hepatitis delta virusom pomoću interferona lambda |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953072B2 (https=) |
| EP (2) | EP3957319B1 (https=) |
| JP (3) | JP7674628B2 (https=) |
| KR (1) | KR20180110127A (https=) |
| CN (1) | CN108883156A (https=) |
| CY (1) | CY1124220T1 (https=) |
| DK (1) | DK3416675T3 (https=) |
| ES (2) | ES2874592T3 (https=) |
| HR (1) | HRP20210862T1 (https=) |
| HU (1) | HUE055343T2 (https=) |
| LT (1) | LT3416675T (https=) |
| PL (1) | PL3416675T3 (https=) |
| PT (1) | PT3416675T (https=) |
| RS (1) | RS61944B1 (https=) |
| SI (1) | SI3416675T1 (https=) |
| SM (1) | SMT202100335T1 (https=) |
| WO (1) | WO2017143253A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| WO2016172342A1 (en) | 2015-04-21 | 2016-10-27 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| JP7674628B2 (ja) | 2016-02-19 | 2025-05-12 | イーアイティー・ファーマ・インコーポレイテッド | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| GB201621728D0 (en) * | 2016-12-20 | 2017-02-01 | Ucb Biopharma Sprl | Methods |
| CN113286605A (zh) * | 2018-08-23 | 2021-08-20 | 艾格尔峰生物制药有限公司 | 用干扰素λ治疗丁型肝炎病毒感染 |
| KR20220035365A (ko) | 2019-07-18 | 2022-03-22 | 엔요 파마 | 인터페론의 부작용을 감소시키는 방법 |
| US20230070752A1 (en) * | 2019-08-21 | 2023-03-09 | Korea Advanced Institute Of Science And Technology | Novel interferon lambda variant and method of producing the same |
| JP2022552001A (ja) * | 2019-10-16 | 2022-12-14 | アイガー・バイオファーマシューティカルズ・インコーポレイテッド | Ｄ型肝炎ウイルス感染を処置する方法 |
| WO2021159027A1 (en) * | 2020-02-06 | 2021-08-12 | Eiger Biopharmaceuticals, Inc. | Treatment of coronavirus infection with interferon lambda |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927040B2 (en) | 2000-06-30 | 2005-08-09 | Zymogenetics, Inc. | Interferon-like protein Zcyto21 |
| US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| EP1575609A4 (en) | 2002-10-23 | 2010-12-15 | Zymogenetics L L C | METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29 |
| JP2006528679A (ja) | 2003-04-01 | 2006-12-21 | インターミューン インコーポレイテッド | コロナウイルス感染症及びサースを治療するための組成物及び方法 |
| EP1927600A1 (en) | 2003-08-07 | 2008-06-04 | Zymogenetics, Inc. | Homogeneous preparations of IL-28 and IL-29 |
| WO2005097165A2 (en) | 2004-04-02 | 2005-10-20 | Zymogenetics, Inc. | Il-28 and il-29 cysteine mutants for treating viral infection |
| WO2006076014A2 (en) | 2004-04-30 | 2006-07-20 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Interferon-alpha constructs for use in the treatment of sars |
| JP2009502803A (ja) | 2005-07-20 | 2009-01-29 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２８およびｉｌ−２９のシステイン欠失変異体、ならびにそれを用いる抗ウイルス法 |
| CA2616004A1 (en) | 2005-07-20 | 2007-02-01 | Zymogenetics, Inc. | Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders |
| WO2007041713A1 (en) | 2005-10-04 | 2007-04-12 | Zymogenetics, Inc. | Production and purification of il-29 |
| US9155749B2 (en) | 2006-09-14 | 2015-10-13 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| US10071154B2 (en) * | 2008-04-04 | 2018-09-11 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same |
| WO2011088126A2 (en) | 2010-01-13 | 2011-07-21 | Eiger Biopharmaceuticals, Inc. | Treatment of viral infection with prenyltransferase inhibitors |
| TW201247216A (en) | 2011-04-01 | 2012-12-01 | Novartis Ag | Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis delta virus and associated liver diseases |
| BR112013032381B1 (pt) * | 2011-06-14 | 2021-01-12 | Globeimmune, Inc. | composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta |
| BR112014004302A2 (pt) | 2011-08-25 | 2017-06-20 | Nanogen Pharmaceutical Biotechnology | conjugado, composição farmacêutica, processo para preparar um conjugado, métodos para inibir a proliferação de uma célula cancerosa, para tratar um distúrbio, e para tratar um paciente |
| US8454947B1 (en) | 2012-03-01 | 2013-06-04 | Nanogen Pharmaceutical Biotechnology | PEG-interferon lambda 1 conjugates |
| AU2013308045B2 (en) | 2012-08-30 | 2018-10-04 | Replicor Inc. | Methods for the treatment of hepatitis B and hepatitis D infections |
| SG11201503459SA (en) | 2012-11-02 | 2015-06-29 | Pharmacyclics Inc | Tec family kinase inhibitor adjuvant therapy |
| HUE044606T2 (hu) | 2014-05-01 | 2019-11-28 | Eiger Biopharmaceuticals Inc | A hepatitis delta vírusfertõzés kezelése |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| WO2016090107A2 (en) | 2014-12-04 | 2016-06-09 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| WO2016172342A1 (en) | 2015-04-21 | 2016-10-27 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| JP7187315B2 (ja) | 2015-11-04 | 2022-12-12 | アイガー・バイオファーマシューティカルズ・インコーポレイテッド | デルタ型肝炎ウイルス感染の処置 |
| JP7674628B2 (ja) | 2016-02-19 | 2025-05-12 | イーアイティー・ファーマ・インコーポレイテッド | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| GB201621728D0 (en) | 2016-12-20 | 2017-02-01 | Ucb Biopharma Sprl | Methods |
| CN113286605A (zh) | 2018-08-23 | 2021-08-20 | 艾格尔峰生物制药有限公司 | 用干扰素λ治疗丁型肝炎病毒感染 |
| WO2021055714A1 (en) | 2019-09-19 | 2021-03-25 | Eip Pharma, Inc. | Compositions and methods for treating prion disease |
| WO2021159027A1 (en) | 2020-02-06 | 2021-08-12 | Eiger Biopharmaceuticals, Inc. | Treatment of coronavirus infection with interferon lambda |
-
2017
- 2017-02-17 JP JP2018543599A patent/JP7674628B2/ja active Active
- 2017-02-17 EP EP21164362.2A patent/EP3957319B1/en active Active
- 2017-02-17 LT LTEP17753966.5T patent/LT3416675T/lt unknown
- 2017-02-17 EP EP17753966.5A patent/EP3416675B9/en active Active
- 2017-02-17 DK DK17753966.5T patent/DK3416675T3/da active
- 2017-02-17 HR HRP20210862TT patent/HRP20210862T1/hr unknown
- 2017-02-17 WO PCT/US2017/018466 patent/WO2017143253A1/en not_active Ceased
- 2017-02-17 RS RS20210703A patent/RS61944B1/sr unknown
- 2017-02-17 US US15/999,239 patent/US10953072B2/en active Active
- 2017-02-17 CN CN201780020097.4A patent/CN108883156A/zh active Pending
- 2017-02-17 PT PT177539665T patent/PT3416675T/pt unknown
- 2017-02-17 SI SI201730795T patent/SI3416675T1/sl unknown
- 2017-02-17 HU HUE17753966A patent/HUE055343T2/hu unknown
- 2017-02-17 ES ES17753966T patent/ES2874592T3/es active Active
- 2017-02-17 SM SM20210335T patent/SMT202100335T1/it unknown
- 2017-02-17 ES ES21164362T patent/ES3008560T3/es active Active
- 2017-02-17 PL PL17753966T patent/PL3416675T3/pl unknown
- 2017-02-17 KR KR1020187026586A patent/KR20180110127A/ko not_active Ceased
-
2021
- 2021-02-18 US US17/178,424 patent/US12508297B2/en active Active
- 2021-06-10 CY CY20211100511T patent/CY1124220T1/el unknown
-
2022
- 2022-09-02 JP JP2022140259A patent/JP2022172279A/ja active Pending
-
2024
- 2024-08-01 JP JP2024125792A patent/JP2024156840A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2874592T3 (es) | 2021-11-05 |
| EP3416675B1 (en) | 2021-03-24 |
| US10953072B2 (en) | 2021-03-23 |
| HUE055343T2 (hu) | 2022-05-28 |
| EP3957319A1 (en) | 2022-02-23 |
| WO2017143253A1 (en) | 2017-08-24 |
| JP2024156840A (ja) | 2024-11-06 |
| JP7674628B2 (ja) | 2025-05-12 |
| US20190111110A1 (en) | 2019-04-18 |
| KR20180110127A (ko) | 2018-10-08 |
| SMT202100335T1 (it) | 2021-07-12 |
| JP2019505553A (ja) | 2019-02-28 |
| SI3416675T1 (sl) | 2021-09-30 |
| RS61944B1 (sr) | 2021-07-30 |
| JP2022172279A (ja) | 2022-11-15 |
| LT3416675T (lt) | 2021-06-25 |
| EP3416675B9 (en) | 2021-07-14 |
| CN108883156A (zh) | 2018-11-23 |
| EP3416675A1 (en) | 2018-12-26 |
| US12508297B2 (en) | 2025-12-30 |
| EP3416675A4 (en) | 2020-01-08 |
| EP3957319B1 (en) | 2024-12-04 |
| US20210228686A1 (en) | 2021-07-29 |
| PT3416675T (pt) | 2021-06-14 |
| CY1124220T1 (el) | 2022-05-27 |
| ES3008560T3 (en) | 2025-03-24 |
| PL3416675T3 (pl) | 2021-10-11 |
| DK3416675T3 (da) | 2021-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210862T1 (hr) | Liječenje infekcije hepatitis delta virusom pomoću interferona lambda | |
| Zhao et al. | Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy | |
| Kao | Hepatitis B vaccination and prevention of hepatocellular carcinoma | |
| Hadziyannis et al. | Treatment of HBeAg-negative chronic hepatitis B | |
| Liaw | Therapy of chronic hepatitis B: current challenges and opportunities | |
| JP2019505553A5 (https=) | ||
| Pramoolsinsup | Management of viral hepatitis B | |
| Zoulim | Are novel combination therapies needed for chronic hepatitis B? | |
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
| Khalfi et al. | Hepatitis D virus: Improving virological knowledge to develop new treatments | |
| Mui et al. | Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention: Hepatitis viruses, human T-cell leukemia viruses, herpesviruses, and Epstein–Barr virus | |
| Rizzetto | Current management of delta hepatitis | |
| Sollima et al. | Recurrence of mixed cryoglobulinaemia vasculitis following influenza vaccination despite clearance of hepatitis C virus infection | |
| Suzuki et al. | Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy | |
| Buster et al. | Peginterferon for the treatment of chronic hepatitis B in the era of nucleos (t) ide analogues | |
| Yao | Management of hepatitis B in China | |
| Kao | Appropriate use of interferon for treatment of chronic hepatitis B | |
| Ozaras et al. | Treating hepatitis B virus/hepatitis C virus coinfected patients with direct‐acting hepatitis C virus antivirals only is not safe | |
| Yüce et al. | Prolonged interferon α treatment in children with chronic hepatitis B | |
| Egwim et al. | Is hepatitis B immunoglobulin prophylaxis needed for liver transplantation in the era of new antivirals? | |
| Villa et al. | Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study | |
| Scotto et al. | Treatment with ribavirin+ alpha interferon in HCV chronic active hepatitis non-responders to interferon alone: preliminary results | |
| Scotto et al. | Efficacy of treatment with lamivudine in patients with chronic active e-minus variant hepatitis B virus infection: a nonrandomized, open-label study | |
| Долимов | HDV infeksiyali bemorlarni davolashda virusga qarshi dori vositalar samaradorligi | |
| Husa et al. | Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons |